• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Exopharm

Exopharm

  • Home
  • Products
  • Partnering
  • Science
  • Resources
    • ASX Announcements
    • Investor Information
    • News & Articles
    • Careers
  • About Us
    • Our Values
    • Our Team
    • Board of Directors
    • Scientific Advisory Board
  • Contact

Understanding and Sharing our Progress at Exopharm

September 4, 2019 By Exopharm Ltd

Exopharm: Preparation, Demonstration and Reward


As a biotech stock, order or to maximise the financial returns from our technologies and products there are a number of aspects to the business of Exopharm. As a headline, we see ourselves as world leaders in a new type of regenerative medicine – harnessing exosomes as the ‘secret sauce’ from stem cells.

Exopharm plans to generate revenue through licensing deals of its products (Plexaris and Exomeres) and its technologies including the purification technology called LEAP.

Some deals may happen independent of clinical trials – examples being potential licensing the LEAP Technology for non-competitive uses and commercialising ‘engineered exosomes’.

The Exopharm business that started in 2013 is similar to a professional football team.

A professional football team is also complex and made up of many parts – players, coaches, management, supporters, funding, recruitment, medical treatment etc.

With a football team, there are three main things happening – preparation, demonstration and then (maybe) reward as year premiers.

Exopharm Sport

PREPARATION

Members of the football team have spent years of preparation and training – on their own and as a team. Preparation is the foundation for success.

DEMONSTRATION

The team needs to demonstrate their skills and determination over many games – the premiers are the ones who play better more often and persevere after a loss.

REWARD

Winning is the ultimate reward and built upon both preparation and demonstration. Turning up is not enough.

Exopharm preparation

Exopharm was started in 2013 with one person. Today Exopharm is a public company, with around 19 employees and around 940 supporters (shareholders).

Our people are collectively highly experienced and cover all of the areas essential for our business – manufacture, analytics, testing, partnering, intellectual property management and investor relations.

We have done our ‘preparation’ and are ‘match-ready’

Exopharm demonstration and reward

So, the next steps for Exopharm are demonstration and reward.

Over the next years our focus is on demonstrating our products, technologies and capabilities and delivering rewards along the way by doing financial deals (‘Licensing’).

Exopharm demonstration

Exopharm is demonstrating:

  • The LEAP purification platform technology – a platform technology with many uses;
  • its core therapeutic products (Plexaris and Exomeres); and
  • other uses of exosomes (sometimes referred to as ‘extracellular vesicles’) and other intellectual property and know-how.

The LEAP purification technology could be partnered as-is. LEAP solves a problem of interest to many companies seeking to progress exosomes as products. Exopharm’s team is extending the capabilities of LEAP and lodging further patent applications to further protect our core manufacturing technology.

Exopharm could potentially license other companies to use LEAP, so long as their activities would not directly compete with our own products (Plexaris or Exomeres).

Exopharm is taking the Plexaris product into clinical trials to demonstrate safety and efficacy – thereby building value and demonstrating the technology. Exopharm also has plans to take the Exomere product into clinical trials. The Plexaris and Exomere products could be partnered after testing.

The LEAP Technology also allows us to build value in areas such as ‘engineered exosomes’ and exosomes as ‘diagnostics’.

Engineered exosomes require exosomes to be loaded up with certain ‘cargo’ or otherwise modified to achieve particular biological outcomes. There are a number of opportunities in the engineered exosomes field that Exopharm is working on.

The use of exosomes as a ‘window’ into the health of patients is another emerging and exciting field in the area of diagnostics. Already this area has attracted merger and acquisition activity and many research publications. There are a number of opportunities in the exosome diagnostic field that Exopharm is working on.

In summary, Exopharm is working hard to demonstrate its value to potential partners across a number of areas.

Exopharm reward

The monetary reward for Exopharm’s shareholders could come from multiple significant financial deals over time.

Deals are already being done in the exosome field. Potential partners are looking at the exosome field and observing progress – some deals are done at relatively early stages if the field is particularly attractive or of strategic importance to the partner. Some deals can be done with preclinical assets/ projects.

With a number of demonstration activities underway, Exopharm will highlight our potential value to partners.

In the biotechnology field it is difficult to anticipate the timing of transactions, but Exopharm has already positioned itself – with a strong team, excellent preparation and a key platform technology.

What this means for shareholders and investors

Sometimes it will be hard for shareholders to see how each pixel of activity fits within the bigger picture.

So, whilst shareholders might focus on a single clinical trial outcome, rewards may surprise.

But if you think about our numerous demonstration activities you will see how they are directed towards delivering multiple rewards.

Filed Under: Opinion Articles

Footer

Resources

  • ASX Announcements
  • Investor Information
  • Board of Directors
  • News & Articles

Information

  • Contact
  • Partnering
  • Join Our Mailing List
  • Privacy, Terms and Conditions
  • Facebook
  • LinkedIn
  • Twitter
  • Vimeo
Copyright © 2022 · Exopharm · ACN 163 765 991 · info@exopharm.com
Level 17/31 Queen St, Melbourne VIC Australia 3000 · P: +61 (0)3 9111 0026 ·

Web Design by Mallee Blue Media
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT